6th AnnualInvitation Only
AML-ALL
USFocus Meeting 2027
Three days, 74 people, one room.
July 8 to 10, 2027
San Diego, CA
Dates
July 8-10, 2027
Three-day program
Venue
San Diego, CA
Hotel TBC
Audience
74 by invitation
37 KOLs & 37 fellows
Format
10 sessions · 40 talks
Plenary, panels + case sessions
A Curated Room: The People Shaping Practice
This sixth annual, invitation-only meeting convenes a deliberately small faculty: 37 leading acute leukemia KOLs alongside 37 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for three days.
The science tracks where treatment is moving: menin inhibitors entering frontline combinations, FLT3 and IDH targeting across lines, HMA+VEN optimization, and bispecifics, ADCs and CAR-T reshaping relapsed and refractory disease. Every session pairs expert talks with a moderated panel, with case presentations threaded through both disease streams, sustained, close-quarters engagement rather than a lecture hall.
Menin InhibitorsFLT3 & IDH TargetingHMA+VEN OptimizationBispecifics, ADCs & CAR-TMRD-Guided StrategyAML · ALL · MDS
Meeting Co-Chairs
Naval Daver
MD Anderson Cancer Center, Houston, TX
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Faculty Drawn From
MD Anderson · Memorial Sloan Kettering · Dana-Farber · Moffitt · City of Hope and other leading US cancer centers
74
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
AML-ALL US Focus Meeting 2027
Faculty
Listed alphabetically by surname
Hussein Abbas
MD Anderson Cancer Center, Houston, TX
Ibrahim Aldoss
City of Hope, Duarte, CA
Jessica Altman
Northwestern University Feinberg School of Medicine, Chicago, IL
Roberta Azevedo
MD Anderson Cancer Center, Houston, TX
Kelly Chien
MD Anderson Cancer Center, Houston, TX
Charles Craddock
Queen Elizabeth Hospital Birmingham, Birmingham, UK
Naval Daver
MD Anderson Cancer Center, Houston, TX
Courtney DiNardo
MD Anderson Cancer Center, Houston, TX
Ann-Kathrin Eisfeld
OSU Comprehensive Cancer Center, Columbus, OH
Amir Fathi
Massachusetts General Hospital, Boston, MA
Guillermo Garcia-Manero
MD Anderson Cancer Center, Houston, TX
Armin Ghobadi
Washington University School of Medicine, St. Louis, MO
Hannah Goulart
MD Anderson Cancer Center, Houston, TX
Fadi Haddad
MD Anderson Cancer Center, Houston, TX
Christopher Hourigan
Virginia Tech FBRI Cancer Research Center, Washington, DC
Ghayas C. Issa
MD Anderson Cancer Center, Houston, TX
Elias Jabbour
MD Anderson Cancer Center, Houston, TX
Nitin Jain
MD Anderson Cancer Center, Houston, TX
Tapan Kadia
MD Anderson Cancer Center, Houston, TX
Hagop Kantarjian
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Aaron Logan
UCSF Health, San Francisco, CA
Sanam Loghavi
MD Anderson Cancer Center, Houston, TX
Marlise Luskin
Dana-Farber Cancer Institute, Boston, MA
Kelly Norsworthy
US Food and Drug Administration, Silver Spring, MD
Susan O’Brien
UCI Health, Orange, CA
Kristen O’Dwyer
University of Rochester Medical Center, Rochester, NY
Jae Park
Memorial Sloan Kettering Cancer Center, New York, NY
Naveen Pemmaraju
MD Anderson Cancer Center, Houston, TX
Alexander Perl
University of Pennsylvania, Philadelphia, PA
Gail J. Roboz
Weill Cornell Medicine, New York, NY
David Sallman
Moffitt Cancer Center, Tampa, FL
Caner Saygin
The University of Chicago Medicine, Chicago, IL
Bijal Shah
Moffitt Cancer Center, Tampa, FL
Nicholas Short
MD Anderson Cancer Center, Houston, TX
Wendy Stock
The University of Chicago Medicine, Chicago, IL
Mahesh Swaminathan
MD Anderson Cancer Center, Houston, TX
Roland Walter
Fred Hutchinson Cancer Center, Seattle, WA
Eunice Wang
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Jun Yang
St. Jude Children’s Research Hospital, Memphis, TN
Amer Zeidan
Yale School of Medicine, New Haven, CT
Joshua Zeidner
UNC School of Medicine, Chapel Hill, NC
Three Days, Ten Sessions
Agenda
Presentations15 min
Panel Discussions30 min
Lunch50 min
20 min
65 min
Day One · Thursday, July 8, 2027
Ohio State University, Columbus, OH
Session ITBD
ModeratorTBD
Updates on CML
Hagop KantarjianMD Anderson Cancer Center, Houston, TX
Updates on CLL
Susan O’BrienUCI Health, Orange, CA
Updates on Low Risk MDS
Rami KomrokjiMoffitt Cancer Center, Tampa, FL
Panel Discussion
Coffee Break & Networking
Session IITBD
ModeratorTBD
Updates on High Risk MDS
Guillermo Garcia-ManeroMD Anderson Cancer Center, Houston, TX
Updates on BPDCN
Naveen PemmarajuMD Anderson Cancer Center, Houston, TX
Case Presentations and Panel Discussion
Fadi Haddad (CML), Mahesh Swaminathan (CLL), Kelly Chien (MDS)MD Anderson Cancer Center, Houston, TX
Panel Discussion & Take-Home Points From Day 1
Adjourn
ModeratorTBC
Adjuvant Therapy for pMMR by Molecular Subgroup (RAINBO, PORTEC-4)
Brad CorrUniversity of Colorado Anschutz, Aurora, CO
Non-dMMR Advanced Recurrent 1L & Optimal Maintenance
Kathleen MooreFred & Pamela Buffett Cancer Center, Omaha, NE
2L+ Endometrial Cancer ADCs & Small Molecules
Bhavana PothuriNYU Langone Health, New York, NY
Young Investigator Case Presentation
TBD
Panel Discussion
ModeratorTBC
What ADCs Are: Beyond Target, Payload & Linker
Paolo TarantinoDana-Farber Cancer Institute, Boston, MA
Toxicities & Need for MDT: ILD, OM, Ocular
BJ RimelCedars-Sinai, Los Angeles, CA
Dose & Regimen Optimization, Including Duration
Bradley MonkFlorida Cancer Specialists, West Palm Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
Day Two · Friday, July 9, 2027
Session IIIPharmacogenomics and Treatment Effect
ModeratorTBD
Pharmacogenomics in ALL
Jun YangSt. Jude Children’s Research Hospital, Memphis, TN
How I Treat Philadelphia-Like ALL
Nitin JainMD Anderson Cancer Center, Houston, TX
How I Treat Ph+ ALL
Marlise LuskinDana-Farber Cancer Institute, Boston, MA
How I Treat Older ALL
Nicholas ShortMD Anderson Cancer Center, Houston, TX
Panel Discussion
Coffee Break & Networking
Session IVTBD
ModeratorTBD
Updates From CAM: Genetic and Molecular Diagnostics in AML
Sanam LoghaviMD Anderson Cancer Center, Houston, TX
Optimization of Intensive Treatment Strategies in Non-FLT3m AML
Tapan KadiaMD Anderson Cancer Center, Houston, TX
Frontline Treatment of FLT3-ITD Mutated AML: Current Approaches and Future Directions
Alexander PerlUniversity of Pennsylvania, Philadelphia, PA
Optimizing Maintenance Approaches in Non-Transplanted Patients With AML
Gail J. RobozWeill Cornell Medicine, New York, NY
Optimizing Post-Transplant Maintenance Approaches and the ACT Platform Successes in SCT
Charles CraddockQueen Elizabeth Hospital Birmingham, Birmingham, UK
Panel Discussion
Lunch Break
Session VTBD
ModeratorTBD
Towards a Chemo-Free Regimen
Elias JabbourMD Anderson Cancer Center, Houston, TX
Updates on North America Cooperative Group Clinical Trials
Wendy StockThe University of Chicago Medicine, Chicago, IL
CAR-T Consolidation in Frontline: Ready for Primetime
Jae ParkMemorial Sloan Kettering Cancer Center, New York, NY
How I Optimize Treatment of T-ALL: The Role of BH3 Mimetics
Kristen O’DwyerUniversity of Rochester Medical Center, Rochester, NY
Panel Discussion
Coffee Break & Networking
Session VITBD
ModeratorTBD
AZA+VEN for All: What Is the Current PARADIGM??
Amir FathiMassachusetts General Hospital, Boston, MA
FLT3 Triplets in AML: What More Is There to Say?
Naval DaverMD Anderson Cancer Center, Houston, TX
How Do I Use IDH Inhibitors in Frontline and R/R AML
Courtney DiNardoMD Anderson Cancer Center, Houston, TX
Selecting Optimal Treatments in R/R FLT3 AML and Understanding Mechanisms of Resistance
Jessica AltmanNorthwestern University Feinberg School of Medicine, Chicago, IL
Using WES for Baseline Assessment and to Track MRD in New AML
Christopher HouriganVirginia Tech FBRI Cancer Research Center, Washington, DC
Panel Discussion
Special LectureFDA Perspectives on Endpoints in AML and Applications of MRD for AML Drug Development
Kelly NorsworthyUS Food and Drug Administration, Silver Spring, MD
Questions & Adjourn
Day Three · Saturday, July 10, 2027
Agenda & Faculty to be Announced
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education
zeynep.aydagul@md-education.com